I am heading the Data Assets and Insights Solutions team focusing on creating impact on our pipeline with FAIRified, enriched, semantically integrated data products (e.g., Hubble) in combination with solutions which provide insights to key scientific and business questions along the entire R&D value chain (e.g. Aelixir).

Make a difference and lifelong learning!

The SCLM4Future project together with the PRINCE (Preclinical Information Center) project as well as the CONDAS (Connecting Data for Science) team is an excellent example for a successful cross-functional collaboration between CD&O, RED preMed and DS&AI within Research & Development but also between Platform IT and external partners. Together the team achieved to overcome legacy manual processes, redundant maintenance work, and functional silos by introducing new digital solutions and concepts with a strong collaborative mindset. The newly released SCLM 2.0 (Standard Codelist Maintenance) & PTO (Preclinical Terminology and Ontology) systems will enable our organization to improve the quality of controlled terminologies with regards to standard codelists and codes while reducing maintenance time and effort. This will have a positive impact on the code/codelist consistency across clinical and preclinical, as well as the compliance to regulatory requirements (e.g. CDISC (Clinical Data Interchange Standard Consortium) Controlled Terminology). The approach to share our knowledge as well as our efforts across functions will be an important step to archive our goals to increase data quality, interoperability and reusability – or to make a long story short: to make our data even more FAIR. For more information contact: Daniela Bergann.

I collaborate with different functions to acquire, process and transform data using technologies for better insights and decision-making for Pharma R&D.​

I've met Miriam during a DS&AI meeting in May 2023 in Madrid. She works as a Data Steward within Data Strategy and Governance in the group Proprietary Information Management. She is a (computational) chemist by training and has particular experience with our chemical labjournal data.

Collaborations with external partners may lead to joint legal rights for compounds and data, which may restrict reusage in other projects. With the increasing number of collaborations at Bayer and with advancing time, memories of the project details fade, and reconstruction of the status will be nearly impossible. Therefore, we aim for a system to document the role of compounds, which will facilitate decisions on further usage in other collaborations. For more information contact: Miriam Wollenhaupt. Images taken from Microsoft Office free for use pictograms.